Tumor budding is an independent prognostic factor in stage III colon cancer patients: A post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR).

[1]  M. Bertagnolli,et al.  Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance). , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  H. Egi,et al.  Tumor budding as a predictive marker for 5-fluorouracil response in adjuvant-treated stage III colorectal cancer , 2021, International Journal of Clinical Oncology.

[3]  I. Nagtegaal,et al.  Tumour budding and CD8+ T cells: ‘attackers’ and ‘defenders’ in rectal cancer with and without neoadjuvant chemoradiotherapy , 2020, Histopathology.

[4]  R. Labianca,et al.  Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. , 2020, The Lancet. Oncology.

[5]  I. Nagtegaal,et al.  Tumour budding in solid cancers , 2020, Nature Reviews Clinical Oncology.

[6]  J. Taieb,et al.  Adjuvant Chemotherapy for Stage III Colon Cancer , 2020, Cancers.

[7]  R. Labianca,et al.  Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  P. Laurent-Puig,et al.  Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Y. Bécouarn,et al.  Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR). , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Cappellesso,et al.  RAS, Cellular Plasticity, and Tumor Budding in Colorectal Cancer , 2019, Front. Oncol..

[11]  N. Tomita,et al.  Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer: Results From the SACURA Trial , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Weinberg,et al.  EMT and Cancer: More Than Meets the Eye. , 2019, Developmental cell.

[13]  E. Pilozzi,et al.  Study of histopathologic parameters to define the prognosis of stage II colon cancer , 2019, International Journal of Colorectal Disease.

[14]  Peter D Caie,et al.  Automated Analysis of Lymphocytic Infiltration, Tumor Budding, and Their Spatial Relationship Improves Prognostic Accuracy in Colorectal Cancer , 2019, Cancer Immunology Research.

[15]  R. Yantiss,et al.  Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline , 2019, Journal of global oncology.

[16]  P. Kuppen,et al.  Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data , 2018, British Journal of Cancer.

[17]  M. Ychou,et al.  Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Labianca,et al.  Duration of Adjuvant Chemotherapy for Stage III Colon Cancer , 2018, The New England journal of medicine.

[19]  Kui-fat Chan,et al.  Tumor budding and poorly-differentiated cluster in prognostication in Stage II colon cancer. , 2018, Pathology, research and practice.

[20]  Phil Quirke,et al.  Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016 , 2017, Modern Pathology.

[21]  A. Jemal,et al.  Colorectal cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[22]  P. Laurent-Puig,et al.  Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  V. Bhatt,et al.  Chemotherapy use in stage III colon cancer: a National Cancer Database analysis , 2015, Therapeutic advances in medical oncology.

[24]  I. Zlobec,et al.  Heterogeneity analysis of Metastasis Associated in Colon Cancer 1 (MACC1) for survival prognosis of colorectal cancer patients: a retrospective cohort study , 2015, BMC Cancer.

[25]  O. Schilling,et al.  Detailed analysis of epithelial‐mesenchymal transition and tumor budding identifies predictors of long‐term survival in pancreatic ductal adenocarcinoma , 2015, Journal of gastroenterology and hepatology.

[26]  F. Marincola,et al.  Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.

[27]  I. Nagtegaal,et al.  Predicting lymph node metastasis in pT1 colorectal cancer: a systematic review of risk factors providing rationale for therapy decisions , 2013, Endoscopy.

[28]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[29]  L. Terracciano,et al.  CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a ‘pro-/anti-tumour’ approach to tumour host interaction in colorectal cancer , 2009, British Journal of Cancer.

[30]  L. Terracciano,et al.  Role of APAF‐1, E‐cadherin and peritumoural lymphocytic infiltration in tumour budding in colorectal cancer , 2007, The Journal of pathology.

[31]  Hidetaka Mochizuki,et al.  Risk factors for an adverse outcome in early invasive colorectal carcinoma. , 2004, Gastroenterology.